ArticleBiology direct2026
VSTM2L mediates the release of extracellular vimentin to drive lymph node metastasis in gastric cancer.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLymph node metastasis (LNM), the most common route of gastric cancer (GC) dissemination, remains poorly understood. This study aimed to elucidate the role of V-Set and Transmembrane Domain Containing 2 Like (VSTM2L) in GC LNM.
methodsVSTM2L expression was evaluated by immunohistochemistry, qPCR, and western blot. Its effects on cell proliferation, invasion, lymphangiogenesis, and metastasis were examined via colony formation, Transwell, tube formation, and in vivo experiments, respectively. Protein interactions were analyzed by immunoprecipitation and GST-pull down. The role of VSTM2L in promoting vimentin secretion was assessed using Ponceau Red staining and Enzyme-Linked Immunosorbent Assay (ELISA). Rescue experiments were conducted to confirm the functional significance of vimentin.
resultsVSTM2L was significantly upregulated in GC cell lines and lymph node-positive tissues, and its high expression correlated with poor survival. Loss- and gain-of-function experiments demonstrated that VSTM2L promotes GC cell proliferation, invasion, and lymphangiogenesis. Mechanistically, VSTM2L interacted with vimentin to enhance its intracellular stability and promote its extracellular secretion. The released vimentin subsequently upregulated focal adhesion complex proteins intracellularly and activated Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) signaling in human lymphatic endothelial cells, leading to cytoskeletal rearrangement and lymphangiogenesis, respectively. Consistent with this mechanism, both in vitro and in vivo evidence confirmed that the secretion of vimentin is essential for the pro-lymphangiogenic effects of VSTM2L.
conclusionsWe identify VSTM2L as a novel and potent driver of LNM. Our findings highlight the therapeutic potential of targeting the VSTM2L-extracellular vimentin axis in GC and elucidate a previously unrecognized mechanism driving vimentin secretion and lymphatic metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.